Clinical trials: Severe Pneumonia With Respiratory Failure
COVID-19 Pneumonia
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells
Novel coronavirus disease COVID-19, produced by SARS-CoV-2, has become a health emergency around the world. Since first patients were detected in Wuhan (China), in December 2019, COVID-19 has spread quickly worldwide, being a…
- Trial name
- MSV-COVID (NCT04361942)
- Testing
- Mesenchymal Stem Cells (MSCs)
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Red de Terapia Celular
Severe Pneumonia With Respiratory Failure
Chinese Adaptive Randomised Pneumonia Trial With Respiratory Failure
1. Background Severe pneumonia with respiratory failure carries a high mortality rate. Preliminary evidence suggests potential benefits for interventions such as Trendelenburg Position and certain herbal formulations used within…
- Trial name
- CARP-RF (NCT07396701)
- Testing
- Trendelenburg Position, Traditional Chinese Medicine Formulation
- Volunteers
- 1,500 people
- Sponsor
- Peking Union Medical College Hospital
COVID-19, Undefined
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired…
- Trial name
- NCT04659122
- Testing
- AT-100
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Airway Therapeutics, Inc.
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS)
Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure
This is a phase I/II, randomized, double-blind, placebo-controlled clinical trial that will evaluate the safety and potential efficacy of therapy with extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs)…
- Conditions
- Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS), Pneumonia
- Trial name
- NCT06002841
- Testing
- intravenous treatment with EVs
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- D'Or Institute for Research and Education
COVID-19, Respiratory Failure
Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS
The aim of the present study is to examine whether cerebral oxygenation could be a more useful parameter than peripheral oxygen saturation to guide clinical titration of permissive hypoxemia in COVID-19 ARDS patients
- Trial name
- NIRS-COV (NCT04392089)
- Testing
- Masimo, LidCO
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hvidovre University Hospital
Infant, Newborn, Hypertension, Pulmonary
Early Inhaled Nitric Oxide for Respiratory Failure in Newborns
This prospective, randomized controlled trial tested whether initiating iNO therapy earlier would reduce death and reduce the use of extracorporeal membrane oxygenation (ECMO) -- temporary lung bypass -- therapy compared with the…
- Conditions
- Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration
- Trial name
- Early iNO (NCT00005773)
- Testing
- Inhaled Nitric Oxide, Standard iNO therapy
- Where
- 18 sites in United States
- Volunteers
- 302 people
- Sponsor
- NICHD Neonatal Research Network
Covid19, Mechanical Ventilation Complication
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation
The principal objective of the CONFIDENT trial is to assess the efficacy of two units (400-500 mL in total) of convalescent plasma, as compared to Standard of Care (SoC), to reduce day-28 mortality in patients with SARS-CoV-2…
- Conditions
- Covid19, Mechanical Ventilation Complication, Corona Virus Infection, Respiratory Failure
- Trial name
- CONFIDENT (NCT04558476)
- Testing
- Convalescent Plasma, Standard of Care
- Where
- 17 sites in Belgium
- Volunteers
- 475 people
- Sponsor
- University of Liege
Respiration Disorders, Respiratory Failure
Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis
Aim of the research: To find out why antibiotics work differently in certain patients with severe pneumonia and sepsis. Background: Individuals can become very unwell from pneumonia, sometimes requiring admission to hospital or…
- Conditions
- Respiration Disorders, Respiratory Failure, Sepsis, Infection in ICU
- Trial name
- SIPRES (NCT06977165)
- Testing
- Antibiotic quantification
- Where
- United Kingdom
- Volunteers
- 119 people
- Sponsor
- University of Manchester